<SEC-DOCUMENT>0001079973-25-000056.txt : 20250113
<SEC-HEADER>0001079973-25-000056.hdr.sgml : 20250113
<ACCEPTANCE-DATETIME>20250113160858
ACCESSION NUMBER:		0001079973-25-000056
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250113

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AEON Biopharma, Inc.
		CENTRAL INDEX KEY:			0001837607
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				853940478
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-92271
		FILM NUMBER:		25526457

	BUSINESS ADDRESS:	
		STREET 1:		5 PARK PLAZA
		STREET 2:		SUITE 1750
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92614
		BUSINESS PHONE:		(949) 354-6499

	MAIL ADDRESS:	
		STREET 1:		5 PARK PLAZA
		STREET 2:		SUITE 1750
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92614

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Priveterra Acquisition Corp.
		DATE OF NAME CHANGE:	20201222

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			L1 Capital Global Opportunities Master Fund, Ltd.
		CENTRAL INDEX KEY:			0001702202
		ORGANIZATION NAME:           	
		IRS NUMBER:				981241877
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G

	BUSINESS ADDRESS:	
		STREET 1:		161A SHEDDEN ROAD ONE ARTILLERY COURT
		STREET 2:		P.O. BOX 10085
		CITY:			GRAND CAYMAN
		STATE:			E9
		ZIP:			KY1-1001
		BUSINESS PHONE:		646-688-5654

	MAIL ADDRESS:	
		STREET 1:		161A SHEDDEN ROAD ONE ARTILLERY COURT
		STREET 2:		P.O. BOX 10085
		CITY:			GRAND CAYMAN
		STATE:			E9
		ZIP:			KY1-1001
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: L1 Capital Global Opportunities Master Fund, Ltd. -->
          <cik>0001702202</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <securitiesClassTitle>Class A Common Stock, par value $0.0001 per share</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>01/06/2025</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001837607</issuerCik>
        <issuerName>AEON Biopharma, Inc.</issuerName>
        <issuerCusip>00791X100</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>5 Park Plaza, Suite 1750</com:street1>
          <com:city>Irvine</com:city>
          <com:stateOrCountry>CA</com:stateOrCountry>
          <com:zipCode>92614</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>L1 Capital Global Opportunities Master Fund, Ltd.</reportingPersonName>
      <citizenshipOrOrganization>E9</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>8960000.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>8960000.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>8960000.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>9.99</classPercent>
      <typeOfReportingPerson>FI</typeOfReportingPerson>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>AEON Biopharma, Inc.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>5 Park Plaza, Suite 1750, Irvine, CA 92614</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>L1 Capital Global Opportunities Master Fund, Ltd.</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>161A Shedden Road, 1 Artillery Court
PO Box 10085
Grand Cayman, Cayman Islands KY1-1001</principalBusinessOfficeOrResidenceAddress>
        <citizenship>Cayman Islands</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>8,960,000

The amounts in Row (5), (7) and (9) represent 6,000,000 Class A Common Stock and 2,960,000 Class A Warrants. The amounts do not include 3,040,000 Class A Warrants nor 6,000,000 Class B Warrants, which are subject to a 9.99% beneficial ownership limitation. The percentage set forth on Row (11) of the cover page for the reporting person is based on 89,627,288 Class A Common Stock outstanding immediately after the offering based upon the Issuer's Prospectus Supplement filed under Rule 424(b)(5) with the Securities and Exchange Commission on January 6, 2025.

David Feldman and Joel Arber are the Directors of L1 Capital Global Opportunities Master Fund, Ltd. As such, L1 Capital Global Opportunities Master Fund, Ltd., Mr. Feldman, and Mr. Arber may be deemed to beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934) the issuer's securities described herein. To the extent Mr. Feldman and Mr. Arber are deemed to beneficially own such securities, Mr. Feldman and Mr. Arber disclaim beneficial ownership of these securities for all other purposes.</amountBeneficiallyOwned>
        <classPercent>9.99</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>8,960,000</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>0</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>8,960,000</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>0</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>Y</notApplicableFlag>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
      </item10>
    </items>
    <signatureInformation>
      <reportingPersonName>L1 Capital Global Opportunities Master Fund, Ltd.</reportingPersonName>
      <signatureDetails>
        <signature>/s/ David Feldman</signature>
        <title>David Feldman, Director</title>
        <date>01/13/2025</date>
      </signatureDetails>
    </signatureInformation>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
